Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

uniQure N.V.

http://www.uniqure.com

Latest From uniQure N.V.

Biotech Entrepreneur Aldag Inspired By Italy's Genespire

Jörn Aldag, who has over 20 years of leadership experience in the life sciences industry, including CEO of gene therapy pioneer uniQure, tells Scrip that the research carried at the world-class Italian research institute SR-Tiget.

Gene Therapy Appointments

Vico Therapeutics' RNA Modulators For Neurological Diseases Attract Series A Funding

A Netherlands start-up Vico Therapeutics could start clinical trials in late 2021 with its antisense approach to the treatment of rare neurological diseases, financed by its large Series A.

Financing Neurology

Stockwatch: Age And Outcome Duration Cloud Innovative Therapy Reimbursement

Gene and cellular therapies that can replace decades of expensive therapy do not come cheap. Even the initial remedy of payment by installments could be irrelevant when not all patients respond in the same way.

Gene Therapy Reimbursement

uniQure Hemophilia B Deal With CSL Leaves M&A Fans Miffed

Observers have been expecting uniQure to be sold off as a whole but the Netherlands-based firm has chosen to sell just one asset - EtranaDez - and focus on advancing its Huntington’s disease gene therapy.

Gene Therapy Blood & Coagulation Disorders
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Drug Delivery
  • Biotechnology
    • Antisense, Oligonucleotides
    • Gene Therapy, Cell Therapy
    • Large Molecule
  • Other Names / Subsidiaries
    • Amsterdam Molecular Therapeutics (AMT)
    • InoCard GmbH
    • uniQure Germany GmbH
    • uniQure U.S.A.
    • uniQure The Netherlands
    • uniQure Inc.
UsernamePublicRestriction

Register